2022年4月22日，歐盟食品安全局（EFSA）發布消息，歐盟食品安全局（EFSA）發布關于柚皮苷（naringin）作為所有動物飼料添加劑的授權更新申請的評估。
經過評估，專家小組得出結論，該添加劑在授權使用條件下對所有動物物種、消費者和環境都是安全的。在缺乏數據的情況下，評估小組無法就添加劑的皮膚過敏潛力得出結論。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for the renewal of authorisation of naringin as a sensory additive for all animal species. The applicant provided data demonstrating that the additive currently in the market complies with the conditions of authorisation. The FEEDAP Panel confirms that the use of naringin under the current authorised conditions of use is safe for the target species, the consumers and the environment. Naringin does not cause severe irritation or corrosion to eyes, is not irritant to the skin and is not classified as a dermal sensitiser. The FEEDAP Panel cannot conclude on the possible respiratory sensitisation of the additive, due to the lack of data. There was no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
經過評估，專家小組得出結論，該添加劑在授權使用條件下對所有動物物種、消費者和環境都是安全的。在缺乏數據的情況下，評估小組無法就添加劑的皮膚過敏潛力得出結論。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for the renewal of authorisation of naringin as a sensory additive for all animal species. The applicant provided data demonstrating that the additive currently in the market complies with the conditions of authorisation. The FEEDAP Panel confirms that the use of naringin under the current authorised conditions of use is safe for the target species, the consumers and the environment. Naringin does not cause severe irritation or corrosion to eyes, is not irritant to the skin and is not classified as a dermal sensitiser. The FEEDAP Panel cannot conclude on the possible respiratory sensitisation of the additive, due to the lack of data. There was no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
